Wockhardt has set an ambitious timeline for securing European regulatory approval for its pharmaceutical product Zaynich, targeting July 2026 as the completion date for this critical milestone.

Regulatory Timeline and Strategic Focus

The company's announcement regarding Zaynich reflects its strategic approach to international market expansion. The July 2026 target date provides a clear timeline for stakeholders and demonstrates the company's commitment to navigating the European regulatory landscape.

Market Expansion Strategy

The European approval timeline represents a significant component of Wockhardt's broader international expansion strategy. Securing regulatory approval in European markets would potentially open new revenue streams and strengthen the company's global pharmaceutical presence.

Regulatory Pathway Forward

The targeted July 2026 approval date suggests that Wockhardt is actively engaged in the regulatory submission and review process with European authorities. This timeline indicates the company's confidence in meeting the stringent requirements set by European regulatory bodies for pharmaceutical product approvals.

Wockhardt Limited has informed stock exchanges about receiving a GST demand order of ₹90.23 lakhs from tax authorities for the financial year 2019-20. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

GST Demand Order Details

The company received the tax demand order dated December 26, 2025, from the Superintendent, Central GST Range-11, Division-III, Ghaziabad. The total demand amount includes both the principal tax liability and penalties imposed by the authorities.

Nature of GST Violation

The demand has been raised due to adjustment of GST amount in the returns filed for FY 2019-20. According to the company's disclosure, the issue stems from excess GST paid during earlier years, which required adjustments in the subsequent financial year returns. The demand arose as part of the regular yearly assessment under current GST provisions.

Company's Response and Impact Assessment

Wockhardt Limited has expressed its disagreement with the demand order and announced plans to file an appropriate appeal against the tax authorities' decision. The company emphasized that this demand order will have no material impact on its financial position, operations, or other business activities.

The pharmaceutical company clarified that the GST demand emerged through routine assessment procedures and would not affect its ongoing operations. Management has assured stakeholders that necessary steps are being taken to contest the order through proper legal channels.

Regulatory Compliance and Disclosure

The company acknowledged a delay in making this disclosure to the stock exchanges, attributing it to an inadvertent administrative oversight. The disclosure was made upon realization of the omission, ensuring compliance with regulatory requirements.

Wockhardt Limited has confirmed that this intimation is also available on the company's official website at www.wockhardt.com , maintaining transparency with all stakeholders regarding this regulatory development.